Events

Events

Brisbane, Australia – Oral Presentation and Posters
Alexandre Le Vert, Chief Executive Officer & Co-founder of Osivax, to provide a clinical update on OVX836 as part of a presentation entitled “OVX836, A NP-Based Universal Influenza Vaccine Candidate, Triggers Effector CD4+ and Cytotoxic CD8+ T-Cells in Healthy Adults”. 

Delphine Guyon-Gellin, Chief of Business Development & Chief Operating Officer of Osivax, to provide additional data as part of two posters entitled (i) “OVX836, A NP-Based Broad-Spectrum Influenza Vaccine Candidate, is Safe, Immunogenic and Triggers Cross-reactive immune response in older adults”, and (ii) “Results of a Second Phase 2 Study Evaluating the Concomittant Administration of OVX836 with Standard Flu Vaccines: Compelling Safety and Immunogenicity”.

Two more posters on preclinical data entitled “OVX033, N-Based T-Cell Broad-Spectrum Vaccine Candidate Against all Sarbecovirus is Safe and Immunogenic in Non-Human Primates” and “A Mix of OVX836, a NP-based T-cell Influenza Vaccine Candidate, with a Commercial Seasonal Vaccine is Immunogenic and Synergistically Protective in Mice” are also presented.

Online – Oral Presentation
Charlotte Primard, Non-Clinical Project Manager of Osivax, to provide an update on OVX033 as part of a presentation entitled “Immunogenicity, cross-reactivity and poly-functionality of immune responses induced by OVX033 with and without SQ for SARS-CoV-2”. 

Lyon – Oral Presentation and Poster
Florence Nicolas, Chief Development Officer and co-founder of Osivax, to provide a clinical update on OVX836 as part of a presentation entitled « Clinical update of OVX836, a novel Universal Type A influenza vaccine candidate ». 


Charlotte Primard, Preclinical Project Manager at Osivax, to present a poster entitled « Cross-reactivity of the immune response triggered in a phase 2 study by a novel, broad-spectrum Influenza vaccine candidate ». 

Barcelona – Presentation
Alexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide a clinical update on OVX836 as part of a presentation entitled “Clinical update of OVX836, a novel Universal Type A influenza vaccine candidate ”. 

IDWeek 2023

Boston, MA – Poster
Alexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide a clinical update on OVX836 as part of a poster. 

17th Vaccine Congress

Glasgow – Posters
Alexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide a clinical update on OVX836 and additional data on the cross-reactivity of the immune responses as part of two posters. 

9th ESWI 2023

Valencia – Posters
Delphine Guyon-Gellin, Chief Business Development Officer of Osivax, to provide a clinical update on OVX836 as part of a poster entitled « Co-Administration of OVX836, NP-Based Universal Influenza Vaccine Candidate, with Conventional HA-Based Influenza Vaccine: Results of Phase 2a Clinical Trial ». 

Florence Nicolas, Chief Development Officer and Co-founder of Osivax, to provide additional data on the cross-reactivity of the immune responses as part of a poster entitled « Cross-Reactivity of the Immune Response Triggered in a Phase 2 Study by a Novel, Broad-Spectrum Influenza Vaccine Candidate ».

Washington, DC – Oral Presentation
Alexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide a clinical update on OVX836 as part of a presentation entitled “Clinical Phase 2 immunogenicity results on OVX836 first-in-class broad-spectrum influenza vaccine in elderly patients”. 

Barcelona – Presentation
Alexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide a clinical update on OVX836 as part of a presentation entitled “Clinical Development Update on OVX836 disruptive T-cell vaccin for broad-protection against multiple influenza strains”. 

Belfast – Oral Presentation and Posters
Delphine Guyon-Gellin, Chief of Business Development of Osivax, to provide preclinical results obtained with OVX033 as part of a presentation entitled “OVX033, T-cell based vaccine targeting the nucleocapsid provides broad-spectrum protection against SARS-COV-2 VoC in Hamster challenge model”. Two more posters entitled “Results of a phase 2 study with OVX836 suggest effectiveness in preventing Influenza-Like Illness and confirm good safety profile” and “How to drastically improve influenza prevention: the addition of a T-cell component to increase current vaccine efficacy, preclinical and early clinical results” are also presented.

Oxford – Oral Presentation
Delphine Guyon-Gellin, Chief of Business Development of Osivax, to provide latest clinical results obtained with OVX836 as part of a presentation entitled “Results of a phase 2 study with OVX836 suggest effectiveness in preventing Influenza-Like Illness and confirm good safety profile”. 

Washington DC – Presentation
Alexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide a clinical update on OVX836 as part of a presentation entitled “Clinical Development Update on OVX836 disruptive T-cell vaccine for broad-protection against multiple influenza strains”. 

Virtual – Presentation
Alexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide a clinical update on OVX836 as part of a presentation entitled “OVX836, a next generation universal Influenza vaccine focusing on T-Cell responses: Update on the clinical development plan”. 

8th ESWI 2021

Virtual – Poster
Alexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to present additional efficacy endpoints of OVX836 as part of a poster entitled « OVX836, NP-based universal influenza vaccine candidate: results of phase 2a clinical trial ».